Alector (ALEC) Cash & Current Investments (2018 - 2026)
Alector's (ALEC) quarterly Cash & Current Investments came in at $206.5 million in Q1 2026, down 41.75% year-on-year from $354.6 million in Q1 2025, and down 19.34% on a QoQ basis from $256.0 million in Q4 2025.
Alector (ALEC) Cash & Current Investments (2018 - 2026) Analysis & Trends
Alector (ALEC) has 9 years of Cash & Current Investments data on file, last reported at $206.5 million in Q1 2026.
- On a quarterly basis, Cash & Current Investments fell 41.75% year-over-year to $206.5 million in Q1 2026; TTM through Mar 2026 was $206.5 million, a 41.75% decrease from a year earlier, with the FY2025 full-year figure at $256.0 million, down 38.07% from the prior year.
- Cash & Current Investments for Q1 2026 stood at $206.5 million, down from $256.0 million in the prior quarter.
- Over the last five years, Cash & Current Investments for ALEC reached as high as $868.6 million in Q1 2022 and fell as low as $206.5 million in Q1 2026.
- Historically, Cash & Current Investments has averaged $525.7 million across 5 years, with a median of $548.9 million in 2023.
- Across the five-year window, Cash & Current Investments soared 153.11% in 2022 and sank 41.75% in 2026, its largest moves.
- Year by year, Cash & Current Investments stood at $712.9 million in 2022, then fell by 23.0% to $548.9 million in 2023, then slipped by 24.68% to $413.4 million in 2024, then slumped by 38.07% to $256.0 million in 2025, then declined by 19.34% to $206.5 million in 2026.
- Per Business Quant data, the three most recent Cash & Current Investments figures were $206.5 million in Q1 2026, $256.0 million in Q4 2025, and $291.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,719.23 Bn | 65,718.94 Bn | - | 283.54 Mn |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | 61.40 Mn |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 471.85 Bn | 467.06 Bn | 1.35 Bn | 4.79 Bn |
| 5 | Vertex Pharmaceuticals | 122.29 Bn | 115.04 Bn | 2.59 Bn | 7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 70.04 Bn | 61.28 Bn | 3.31 Bn | 8.75 Bn |
| 7 | Belite Bio | 62.06 Bn | 62.06 Bn | - | - |
| 8 | Argenx Se | 55.78 Bn | 50.60 Bn | 1.41 Bn | 5.18 Bn |
| 9 | Alnylam Pharmaceuticals | 37.47 Bn | 34.47 Bn | 959.66 Mn | 3.01 Bn |
| 10 | Alector | 167.54 Mn | -38.97 Mn | - | 206.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 206.52 Mn |
| Dec 31, 2025 | 256.02 Mn |
| Sep 30, 2025 | 291.11 Mn |
| Jun 30, 2025 | 307.28 Mn |
| Mar 31, 2025 | 354.55 Mn |
| Dec 31, 2024 | 413.40 Mn |
| Sep 30, 2024 | 457.20 Mn |
| Jun 30, 2024 | 503.33 Mn |
| Mar 31, 2024 | 562.08 Mn |
| Dec 31, 2023 | 548.86 Mn |
| Sep 30, 2023 | 588.86 Mn |
| Jun 30, 2023 | 630.05 Mn |
| Mar 31, 2023 | 669.33 Mn |
| Dec 31, 2022 | 712.85 Mn |
| Sep 30, 2022 | 758.31 Mn |
| Jun 30, 2022 | 808.86 Mn |
| Mar 31, 2022 | 868.57 Mn |
| Dec 31, 2021 | 735.25 Mn |
| Sep 30, 2021 | 777.85 Mn |
| Jun 30, 2021 | 319.57 Mn |